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Introduction .  Anastrozole is a chemotherapeutic drug used to treat breast cancer in postmenopausal women. The 
condition for success of this type of treatment is the presence of estrogen receptors in cancer cells. Anastrozole belongs 
to strong-acting, nonsteroidal inhibitors of aromatase, which is responsible for androgen-estrogen conversion process. 
The metabolism of this drug is based on biotransformation both in phase I and II. Initially it metabolizes in the liver with 
cytochrome P450 isoenzymes, followed by a glucuronidation reaction catalyzed by the UGT1A4 enzyme.
Material and method .  In order to minimize the side effects, new therapeutic approaches are sought to increase the 
success of the therapy. 
Conclusions .  Biodegradable nano-tools that deliver anastrozole to the target site with an increase in its half-life to 144 
hours are a promising method. A similar effect can be achieved by using a transdermal anastrozole administration system, 
which is a completely non-invasive method of treatment.
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Introduction
Breast cancer depends on many factors. One of the important 
elements of risk is the age of the patient – the risk of falling ill 
increases with age (up to a certain age limit). The vast majority 
of breast cancers concern women in postmenopausal age. 
Paradoxically, breast tumors in postmenopausal women show 
favorable prognosis associated with increased expression 
of steroid sex hormones receptors. Estrogens, belonging to 
the group of steroid sex hormones, support the growth and 
survival of both normal and cancer cells. This is made possible 
by the binding and activation of the estrogen receptor (ER). Its 
presence in neoplastic cells, i.e. the type of neoplasm defined 
as ER+, is found in most breast neoplasms. This indicates a 
good prognosis of patient survival with the use of pharmaco-
logical treatment with anti-estrogens. An estrogen receptor 
activated by 17-β-estradiol works on the basis of a transcrip-
tion factor that activates the expression of specific genes. They 
are mainly responsible for cell growth, prolonged survival and 
proliferation of cancer cells. Since in most cases the incidence 
of breast cancer depends on the level of hormones, it can 
be considered that hormone therapy can be an effective 
method of complementary treatment. There are three ways 
in which estrogen-dependent processes, important for the 
development and progression of most breast cancers, can 
be inhibited. The first is impacting the estrogen binding with 
the ER and/or the elements of the gene promoter it codes. 
An example of such action are selective ER modulators, i.e. 
tamoxifen and raloxifene. The second method is to reduce 
or eliminate the expression of ER, which is shown by the 
fulvestrant – a selective regulator decreasing ER. However, 
the most effective way of therapy is to reduce the amount of 
estrogen by inhibiting its production. Such pattern of action 
is demonstrated by aromatase inhibitors (AI), which include 
anastrozole (Fig. 1). The factor determining their effectiveness 
is the sensitivity of cancer cells to hormones, i.e. the presence 
of estrogen receptors in them [1, 2].
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Importance of anastrozole in clinical practice
Based on the available published data, anastrozole can be con-
sidered the most selective third generation aromatase inhibitor 
in clinical conditions. It does not reveal a weakened response 
to adrenocorticotropic hormone (ACTH) stimulation even after 
10 administrations of normal clinical dose of anastrozole for 
4 weeks, which suggests that anastrozole therapy does not 
affect adrenal cortex hormone synthesis [3].
Anastrozole was the first aromatase inhibitor to show signi-
ficant survival benefits compared to the standard second-line 
drug: megestrol acetate. Two phase III clinical trials after 6 mon-
ths have shown that anastrozole at 1 mg daily is as effective 
as megestrol acetate, but its use did not affect the significant 
weight gain observed when megestrol acetate was admini-
stered. This analysis also showed a higher median survival rate 
for the benefit of anastrozole (22.5 months in the megestrol 
acetate group vs 26.9 months in the anastrozole group). No 
additional benefit was observed after increasing the dose to 
10 mg, thus supporting the choice of 1 mg as a clinical dose. 
Anastrozole was subsequently approved by the US Food and 
Drug Administration for use in the second line of treatment 
for postmenopausal women with advanced breast cancer [4].
In 2000, two clinical programs were developed to com-
pare the efficacy and tolerance of anastrozole and tamoxifen 
in women with advanced breast cancer. Programs: “TARGET” 
(Tamoxifen or Arimidex TM Randomized Group Efficiency and 
Tolerability) and “North American” included patients with 
newly diagnosed disease or cancer progression following 
previous treatment. They have been randomly assigned to 
a dose of 1 mg anastrozole daily or 20 mg of tamoxifen 
daily. The results of the “North American” study showed a 
clear superiority of anastrozole over tamoxifen in terms of 
disease progression time (TTP = 11.1 months for anastrozole 
and 5.6 months for tamoxifen). A 44% longer survival time 
without disease was also shown for patients receiving ana-
strozole compared to patients treated with tamoxifen. The 
TARGET study also confirmed beneficial effects of anastrozole 
compared to tamoxifen. After obtaining the results of these 
studies, anastrozole has been approved in many countries 
as a first-line treatment for advanced breast cancer in post-
menopausal women [3]. 
It also meets the necessary criteria to be considered ef-
fective as a complementary treatment in postmenopausal 
women. These criteria include: better efficacy if compared 
with the existing adjuvant agents, better tolerance and easy 
and convenient dosage [3].
The latest FACE (Final Anastrozole Clinical Evaluation) study 
was designed to evaluate the efficacy and safety of adjuvant 
letrozole (LET) compared to anastrozole (ANA) in postmeno-
pausal breast cancer patients with hormone receptor-positive 
breast cancers. The total number of patients was 4170, which 
were randomly assigned to the group receiving letrozole (n = 
2076) or anastrozole (n = 2094). For 5 years they were admini-
stered a standard clinical dose of anastrozole (1 mg daily) or le-
trozole (2.5 mg daily). The primary endpoint of the study was a 
5-year disease-free survival (DFS). The key secondary endpoints 
were security and overall survival (OS). The five-year estimated 
DFS ratio was 84.9% for LET and 82.9% for ANA, while the OS 
ratio was 89.9% (LET) and 89.2% (ANA). The main reasons of 
treatment discontinuation in the letrozole arm compared to 
the anastrozole arm were side effects (15.1% vs 14.3%) and 
disease progression (9.5% vs 10.4%). The safety profiles were 
similar in both treatment arms. The most common side effects 
of letrozole compared to anastrozole were: joint pain (48.2% 
vs 47.9%), hot flushes (32.5% vs 32.3%) and fatigue (16.8% vs 
16.6%). Suspected adverse reactions leading to discontinuation 
of treatment were reported in 14.0% of LET patients and 12.9% 
of ANA patients respectively [5].
P450 as estrogen metabolizing enzymes
Cytochrome P450 isoenzymes play an important role in the 
biosynthesis of bioactive compounds such as sterols, steroid 
hormones, eicosanoids and vitamins. Moreover, they partici-
pate in the detoxification of xenobiotics, but one of their most 
important functions is drug metabolism [6, 7]. Isoenzymes are 
also involved in the metabolism of estrogens. The addition of 
hydroxyl group at C-2 position is the main metabolic pathway 
of estradiol in the liver mediated by P450 1A2, 2C8, 2C9 and 
3A4. Estrogens undergo biotransformation as a result of 2/4-hy-
droxylation reaction, catalyzed mainly by P450 3A4 at the ortho 
position to the 3-phenol 2/4-hydroxyestrogen form. These 
metabolites are then converted to 2/4-methoxy-estrogens 
with catechol-O-methyltransferase (COMT). P450 enzymes 
also catalyze the hydroxylation reaction at position 16-α, which 
results in the formation of 6α-hydroxyestrone (Fig. 2) [8, 9].
Aromatase (P450 19) is an enzymatic complex, responsible 
for catalyzing the biosynthesis of estrogens from androgens, 
associated with endoplasmic reticulum in cells. This complex 
is coded by a single CYP19 gene located in the human chro-
mosome 15 at position 21.2. Aromatase is also called estrogen 
synthetase, which consists of two functional proteins. The 
first one is the P450 cytochrome, called monooxygenase. The 
second is a non-specific flavoprotein microsomal reductase, 
also known as NADPH cytochrome P450 reductase, used as 
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Figure 1 . Chemical structure of anastrozole
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a cofactor, nicotinamide adenine dinucleotide. In addition, 
aromatase is highly expressed in Graafian follicles and placenta. 
In postmenopausal women, most estrogens are produced by 
adrenal cortex. Aromatase in low concentrations also occurs in 
breast tissue, adipose tissue, brain, liver and muscles [10–12].
Androgens such as testosterone, dihydrotestosterone and 
androstenedione are converted to estrogens using cytochro-
me P450 aromatase (Fig. 3). Estrogens are formed as a result 
of the loss of the C-19 lateral methyl group in androgens and 
the formation of an aromatic ring. Estrone (E1) is synthesized 
from androstenedione and estradiol (E2) from testosterone. 
The aromatization reaction, i.e. the formation of an aromatic 
ring, is directly catalyzed with the participation of P450 19.
The most important step in this process is the elimination 
of the C-19 group, which enables the aromatization of the A 
ring in the molecule. This process takes place after three oxi-
dation reactions beginning with hydroxylation of the methyl 
group at C-19 position. The last stage is a reaction eliminating 
the rest of C-19 as formic acid. The product created by the 
keto-enol tautomerism strives to aromatize the A ring. To trans-
form the androstenedione molecule to the esterone molecule, 
three NADPH molecules are therefore needed, together with 
oxygen, to form water and nicotinamide adenine dinucleotide 
phosphate (NADP+) during the reaction. In parallel to the 
aromatization, a hydroxylation reaction with NADPH+H+ [12, 
13] takes place.
Anastrozole as active substance
Anastrozole (2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-yl-
methyl)phenyl]-2-methylpropanenitrile) contains in its struc-
ture an aromatic ring with three substituents, which consist 
of methyl, nitrile and triazole groups. It is therefore a chiral 
derivative of triazole catalyzed by P450 cytochrome, which 
results in classifying it as a powerful inhibitor and inductor of 
drug metabolism. Moreover, lipophilic compounds containing 
heterocyclic nitrogen substituents in their structure inhibit 
monooxygenase activity in the liver, with variable affinity of 
binding to microsomal membranes depending on heterocyclic 
substitution position. More lipophilic compounds penetrate 
the membranes more easily and are therefore metabolized 
mainly in the liver by microsomal enzymes. Lipophilicity of 
anastrozole expressed as logPo/w ratio is 1.58 – which means 
that it is a moderately lipophilic compound [14, 15].
The growth and development of breast cancer depends on 
the level of estrogen. Therefore, aromatase inhibitors, which are 
responsible for their biosynthesis, are often used to treat this type 
of cancer. Reducing estrogen levels is the main objective of hor-
mone therapy for the treatment of breast cancer with positive 
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Figure 2 . Estrogen metabolism in the presence of P450 cytochrome enzymes
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hormone receptor effects. Estrogen reduction can be achieved 
in two ways: by blocking the estrogen receptor or by inhibiting 
estrogen biosynthesis with aromatase. The mechanism of action 
of anastrozole should lead to inhibition of estrogen biosynthesis. 
Clinical trials confirm the efficacy of AI interaction with estrogen 
receptor in metastatic breast cancer treatment in postmenopau-
sal women. In addition, a number of studies have confirmed that 
AI are more effective in postmenopausal women than tamoxifen 
commonly used in adjuvant therapy [16].
 AI are divided into two groups in terms of inhibition of 
the aromatization process. The first group, which includes 
exemestane, is irreversibly linked to aromatase and causes its 
permanent inactivation. The second group, which includes ana-
strozole, shows reversible binding to P45019, competing with 
endogenous ligands to the active enzyme site. This is done by 
creating a reversible binding between the N-4 nitrogen group 
in the triazole ring and the iron atom in the active centre of the 
P450 cytochrome (Fig. 4). Anastrozole is therefore a competitive, 
nonsteroid P45019 inhibitor that selectively inhibits the conver-
sion of androgens to estrogens. As result, the concentration of 
estrone, estradiol and estrone sulphate circulating in the serum 
decreases. Inhibition of aromatase by anastrozole consists mainly 
in inhibition of P450 1A2, 2C8, 2C9, 3A4 isoenzymes, which are 
involved in estrogen metabolism [8].
Metabolism of anastrozole 
The effect of a drug in view of biological purposes depends 
on its specific structural modification. This biotransformation 
is most commonly carried out in the liver and its aim is to 
convert lipophilic substances into more hydrophilic metabo-
lites that will be excreted. After being absorbed into the cell, 
the active substance is metabolized, i.e. which is divided into 
two main phases. In the first phase there is an increase in the 
hydrophilicity of drugs, which facilitates and enables their 
excretion. In this phase, oxidation, reduction, elimination and 
hydrolysis reactions occur. Introducing a functional group into 
a drug molecule enables its reaction and then interaction in 
phase II reactions. Oxidation processes are the most important 
biotransformation pathway. They are catalyzed, among others, 
by monoxygenases, which build into xenobiotics one oxygen 
atom coming from an oxygen molecule, while the other one is 
reduced and a water molecule is formed. The most important 
for this phase of metabolism are the enzymes from the family 
of P450 cytochrome, which are catalysts of many biochemical 
transformations [12].
Anastrozole is metabolized in the liver is mainly due to 
hydroxylation – catalyzed by P450 3A4 enzyme and to a les-
ser extent by P450 3A5 enzyme – with hydroxy-anastrozole 
formation. The second important transformation of the drug 
is N-dealkylation, which results in the formation of metabo-
lites: triazole and 3,5-bis-(2-methylpropiononitrile)-benzoic 
acid (Fig. 5). The main anastrozole metabolites identified in 
urine and plasma after phase I of elimination are triazole and 
hydroxy-anastrozole. Triazole shows a predominance as the 
main metabolite circulating in serum of anastrozole-treated 
patients. It is pharmacologically inactive [17–19].
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Figure 3 . A reaction catalyzed by aromatase. Loss of lateral C-19 group with formation of an aromatic ring
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The metabolism of phase II is based on coupling reactions 
catalyzed by specific transferases. In most cases, as a result 
of these reactions, a group is introduced into the xenobiotic 
molecule, which increases hydrophilicity, which in turn in-
creases solubility in water. The resulting conjugates are then 
excreted in urine or bile. The purpose of the coupling reaction 
is to deactivate biological activity or to detoxify, so that the 
products of these reactions are in most cases biologically 
inactive. Coupling with active glucuronic acid (UDP) plays a 
special role in the metabolism of anastrozole. Because of the 
additional -OH hydroxyl groups in its structure, it is considered 
a relatively strong acid and a strongly hydrophilic compound. 
Its transfer to a specific substrate occurs after binding on 
the cell membrane with the UGT enzyme from the family of 
glucuronyltransferases (uridine 5’-diphospho-glucuronosyl-
transferase), which takes place mainly in the liver, kidneys and 
intestines. They are a family of enzymes whose detoxification 
function is based on catalyzing the reaction of glucuronic acid 
coupling with lipophilic substrate containing nucleophilic 
functional group in its structure. As in the case of cytochrome 
P450-dependent monooxidases, many UGT isoenzymes are di-
stinguished. They differ in substrate specificity and expression 
specificity in specific tissues. Similarly to the P450 isoenzymes, 
they show differences in activity, which result from the induc-
tion of enzymatic protein genes. UGT enzymes are capable of 
glucuronidating many structurally diverse endogenous drugs 
and substrates and therefore play an important role in their 
elimination [19, 20].
Studies on anastrozole metabolism show that phase II of 
metabolism is mainly catalyzed by UGT1A4 isoenzyme. More-
over, it was shown that this isoenzyme plays an important role 
in the direct glucuronidation of hydroxy-anastrozole formed 
as a result of oxidation in phase I. According to the results 
obtained, hydroxy-anastrozole was detected and quantified 
in plasma, mainly in conjugated form, as hydroxy-anastrozole 
O-glucuronide, and only to a small extent as non-conjugated 
form. This suggests that the hydroxylated metabolite is ef-
fectively conjugated by UGT enzymes. Anastrozole may also 
be directly glucuronidated to an anastrozole N-glucuronide, 
which is also catalyzed by UGT1A4. This reaction may occur 
on one of the atoms of nitrogen in the triazole ring, hence we 
are talking about N-glucuronidation. However, liver UGT1A4 
is not the only enzyme involved in this reaction. UGT2B7 and 
UGT1A3 are also involved, but to a very small extent [17, 21].
To summarize the changes that anastrozole undergoes, Fig. 
6 presents individual metabolic pathways including enzymes 
involved in them. Thanks to the conducted studies it is believed 
that hydroxylation is the main pathway of oxidation of phase I 
and N-glucuronidation is the main pathway of drug conjugation 
in phase II. This data can serve as a basis for the design of clinical 
drug interactions and pharmacogenetic studies that consider 
metabolism with the P450 3A4 and UGT1A4 enzymes and are de-
signed to predict the clearance of anastrozole, i.e. the a volume of 
plasma from which drug is completely removed per unit of time.
New therapeutic approaches to increase the 
effect of anastrozole
In order to develop an appropriate anticancer therapy, it is 
important to understand the clinical pharmacology of the 
drug in question. Anastrozole has good bioavailability after oral 
Figure 4 . Interaction of steroidal and nonsteroidal inhibitors with aromatase active centre – a) exemestane, b) anastrozole
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administration and is widely distributed in the bloodstream. It 
inhibits the concentration of estrone (E1) by 81-87%, estradiol 
(E2) by 84–85% and estrone sulphate (E1S) by 94% [22]. It is 
intensively metabolized by liver microsomes with a half-life 
of 40–50 hours. It achieves maximum serum concentration 
within two to three hours after oral administration. The stan-
dard dose of anastrozole is 1 mg per day, administered over 
a period of two to five years. This amount is optimal to inhibit 
the biosynthesis of estrogens. Studies in pharmacokinetics of 
anastrozole have shown that it does not affect liver or kidney 
dysfunction. Approximately 10% of the anastrozole dose is 
excreted unchanged in urine, while 60% is excreted in urine 
as metabolites present in urine [16, 23].
However, the use of anastrozole has many adverse side 
effects. These include disorders of the nervous system, mu-
sculoskeletal system, disorders of the stomach and intestines, 
connective tissue, metabolism, nutrition, vascular and general 
symptoms. Their occurrence is a consequence of low solubility 
of anastrozole in water, which quickly removes it from the 
bloodstream, resulting in short plasma half-life (on average 
41–48 hours) and irregular drug intake [3].
Nanotechnology
Nanotechnology is a field of science that is often used to 
overcome the side effects of active pharmaceutical ingredients. 
Particular role is played by nano-tools that provide a targeted 
approach to the administration of site-specific drugs through 
its coupling with carrier molecules such as nanocapsules, na-
nospheres and micelles [24]. Moreover, the trapping of hydro-
phobic compounds within specific nano-tools can significantly 
increase their solubility, delivery efficiency and, consequently, 
effectiveness. Referring to anastrozole, in 2006 Zidan et al. [25] 
published the first paper describing the incapsulation of this 
drug by using biodegradable microparticles based on lactic 
and glycolic acid copolymers (PLGA – poly(lactic-co-glycolic 
acid)). An extended anastrozole administration system was 
used in this case. One of the possible technological solutions 
used to increase the durability of drugs in the target place of 
their action is the application of therapeutic systems based on 
biodegradable polymers. Living matrices have the advantage 
of being biodegradable and gradually disappear, releasing the 
drug directly at the site of activity. Moreover, the administration 
of drugs in the form of microparticles facilitates injection [26].
PLGA has been extensively tested as a polymer carrier for 
biodegradable microspheres. PLGA microparticles have pro-
ven to be an effective means of delivering drugs belonging 
to various classes, including nonsteroidal anticancer drugs 
– which include anastrozole – as well as nonsteroidal anti-in-
flammatory drugs, peptides and steroid hormones. Choosing 
the right polymer composition with a known degradation 
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time allows it to be used in the production of a drug delivery 
system that releases the active ingredient at a predetermined 
rate. Both natural and synthetic polymers are used to pre-
pare such microspheres. The most popular way to produce 
microspheres from PLGA – due to the process repeatability 
and homogeneity of particle size – is emulsification through 
solvent evaporation [25].
Formulated PLGA microspheres loaded with anastrozole 
showed that drug release profiles are characterized by two 
separate phases. The initial release phase occurs on the first day 
followed by a gradual second phase. The profiles of anastro-
zole release from microparticles explain consecutive diffusion 
processes. The diffusion of aqueous, soluble solution into the 
matrix causes the drug to dissolve. Then it diffuses through 
the pores to a soluble medium [27]. Anastrozole in its struc-
ture does not contain any groups susceptible to ionization, 
therefore the change of pH does not affect its solubility [28]. 
Additionally, it has been shown that the drug release rate 
increases with increasing anastrozole load [25].
Another way of supplying anastrozole with nanotechnolo-
gical tools is to use PLA-PEG-PLA nanoparticles, which are also 
biodegradable and non-toxic. They are synthesized from PEG 
Figure 6 . Metabolic pathways of anastrozole including major enzymes involved in drug biotransformation
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(poly(ethylene oxide)), which is recognition-resistant by the im-
mune system. In this case it was combined with PLA polylactide 
(poly(lactic acid)) [29]. This biocompatible system is capable of 
encapsulating anastrozole. In this case, a double emulsion tech-
nique was used, which allows effective delivery of anastrozole 
to the target cells. This system contributed to the prolonged 
release of the drug – up to 144 hours. This prolonged release is 
the result of affinity to the binding between the polymer and 
the drug and the polymer capacity to introduce the drug [30].
 The three-block polymer used for the synthesis of nano-
particles has an amphiphilic character, which makes it suitable 
for incapsulating water-insoluble compounds, including ana-
strozole. Optimal size of nanoparticles is in the range of 10–200 
nm – this allows direct targeting of tumors. Smaller particles 
can be removed and larger ones cannot enter the space of 
the vascular and interstitial tumor. Despite the increase in the 
level of proangiogenic signaling in cancer cells, which causes 
excessive vascularization of the tumor, delivery of the drug 
is possible because these vessels show increased permeabi-
lity. Moreover, tumors are characterized by poor lymphatic 
drainage, which allows to retain macromolecules above 40 
kDa. Therefore, nanoparticles may use features of increased 
permeability and retention directed at solid tumors [31].
The efficacy of such a system was confirmed by cytotoxicity 
studies, which showed the ability of anastrozole-loaded nano-
particles to produce a similar cytotoxic effect compared to a free 
drug. The effectiveness of nanoparticles was also confirmed by 
the observation of expression of apoptotic genes like c-MYC, 
MAPK3 and MCL-1 in MCF-7 breast cancer cells. The MAPK3 gene 
belongs to the kinases activated by myogen, which are a funda-
mental component of the cellular signaling network enabling the 
functioning of cells as an essential part of the organism. C-MYC 
protein is a transcription factor that plays an important role in the 
progression of breast cancer. It is a key regulator of cell cycle, cell 
proliferation and cell transformation. In case of access to survival 
factors, c-MYC deficiency induces apoptosis by activating its pa-
thway through mitochondria and receptors. In turn MCL-1 gene 
is a proapoptotic member of the BCL-2 family of proteins, which 
show features of apoptosis inhibitors. The results of the study 
showed that all three genes were over-expressed, which leads to 
the induction of cancer cell apoptosis and thus directly confirms 
the efficacy of capsule drug delivery to the cells [30].
The use of modern nanotechnological techniques with the 
use of biodegradable polymers leads to prolonged release of 
some active ingredients. For anastrozole, further studies are 
needed to confirm the efficacy of drug-loaded nanoparticles 
and their suitability for clinical use. Any information available 
so far shall cover only in vitro studies involving cancer cell lines. 
Results of studies involving animals are also available [32].
Transdermal drug release
The most commonly used oral anastrozole preparation provi-
des good therapeutic reactions. The maximum plasma concen-
tration of the drug is maintained for approximately 2 hours and 
long-term systemic action with an average half-life of 40 to 50 
hours. However, this is often associated with serious systemic 
adverse reactions. Patients suffering from nausea and vomiting 
are not eligible for oral medication. Transdermal Therapeutic 
Systems (TTS) are therefore a promising alternative and can 
help to avoid adverse side effects [33, 34]. They are a non-invasi-
ve and completely painless method by which a specified, fixed 
dose of the drug is delivered to the bloodstream through the 
skin. Their advantages include an even plasma concentration 
profile, sustained local release and, if necessary, the possibility 
of rapid elimination. 
Oral therapy with aromatase inhibitors leads to uncontrol-
led delivery of a drug characterized by early, maximum drug 
concentration and worse bioavailability, and consequently 
increased number of side effects. On the other hand, low 
molecular weight, high partition coefficient and low melting 
point of anastrozole are favorable physicochemical properties, 
which may ensure its effective penetration through the stra-
tum corneum of the epidermis. 
The kinetics of anastrozole in the transdermal system was 
initially tested in vitro using Franz diffusion cells. The drug load, 
penetration and reinforcement in anastrozole transport were 
evaluated. The prolonged-activity self-adhesive anastrozole 
adhesive was then tested in vivo on beagle breed dogs. The 
patches were placed on the chest and abdomen skin of the 
animals. As expected, a lower initial transfer of anastrozole from 
experimental patches to systemic circulation was observed 
compared to oral drug administration in humans. However, in 
one day the level of anastrozole increased linearly and reached 
the maximum plasma concentration of 4.7 and 5.8 ng/ml at 
the time point Tmax = 24 h. These values corresponded to 34% 
and 42% of the maximum concentration after one oral admi-
nistration of 1 mg of standard human dose of anastrozole [35].
In the case of anastrozole, the ability to control its release 
has many advantages, e.g. prolonged release leads to the 
desired prolonged duration of activity, while the concentra-
tion of the drug is sufficient to ensure adequate therapeutic 
activity. Moreover, it makes it possible to avoid an undesirable 
maximum concentration of the drug in the plasma. In addi-
tion, an easy-to-use system can potentially improve patient 
compliance [35].
Summary
The role of P450 cytochrome P450 in the metabolism of xeno-
biotics has been widely recognized and it is a molecular target 
for breast cancer chemotherapy. Aromatase catalyzing the bio-
synthesis of androgens into estrogens is particularly important 
in this enzymatic complex. It has been shown that inhibition of 
this reaction significantly reduces the level of estrogens in the 
bloodstream and thus limits the growth of tumors depending 
on the level of these hormones. One of the effective aromatase 
inhibitors is anastrozole, a nonsteroidal triazole derivative that 
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inhibits P450 cytochrome 1A2, 2C8, 2C9, 3A4 isoenzymes in-
volved in estrogen metabolism. As an exogenous substance, 
it is also metabolized in relation to enzymes of phase I and II, 
which leads to the formation of its metabolites: 3,5-bis-(2-me-
thylpropiononitrile)-benzoic acid, anastrozole N-glucuronide, 
triazole and hydroxy-anastrozole O-glucuronide. The standard 
dose used in hormonal treatment of postmenopausal women 
is oral intake of 1 mg of the drug daily. This amount is sufficient 
to achieve the desired therapeutic effect, which unfortunately 
also causes numerous side effects.
New methods of administration have been developed to 
reduce the incidence of anastrozole side effects and to increase 
plasma half-life. One of the solutions is the use of nano-tools 
that provide targeted delivery of the drug to increase the ef-
fectiveness of the therapy. For this purpose, the polymers used 
are PLGA, which are carriers of biodegradable micro-particles 
loaded with anastrozole. This system allows controlled release 
of the drug and thus affects the effectiveness of the therapy. 
It is also possible to use a completely non-invasive method of 
delivering the drug, i.e. administering it through the skin. This 
transdermal system allows for an even profile of plasma che-
motherapeutic concentration based on a fixed, defined dose. 
Additionally, the physicochemical properties of anastrozole 
ensure its effective absorption by the epidermis.
The above aspects of anastrozole are the basis for a full 
understanding of both its mechanisms of action and the possi-
bilities of designing new therapeutic approaches that increase 
the effectiveness of anticancer therapies.
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Abbreviations
ER – estrogen receptor
AI – aromatase inhibitor
COMT – catechol-O-methyltransferase
P450 19 – aromatase
E1 – estrone 
E2 – estradiol
E1S – estrone sulphate
NADP+– nicotinamide adenine dinucleotide phosphate
logPo/w – partition coefficient
UDP – glucuronic acid
UGT – uridine 5’-diphospho-glucuronosyltransferase enzyme
PLGA – copolymer of lactic and glycolic acid
PEG – poly(ethylene oxide)
PLA – poly(lactic acid)
TTS – transdermal drug delivery system
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